Imatinib in Patients with Advanced Gastrointestinal Stromal Tumours (Gists)

ZHANG Wen,CHEN Zhi-yu,WANG Lei-ping,HU Xi-chun,CAO Jun-ning,YIN Ji-liang,HONG Xiao-nan,LI Jin
DOI: https://doi.org/10.3969/j.issn.1007-3639.2008.01.010
2008-01-01
Abstract:Background and purpose:GISTs are the most common form of mesenchymal tumor in gastrointestinal tract.GISTs show high-level primary resistance to conventional chemotherapy.This study evaluated the efficacy of the selective tyrosine kinase inhibitor imatinib in the treatment of patients with advanced GISTs.Methods:Sixty patients with measurable advanced GISTs were enrolled into the study and received 400 mg of imatinib daily.Immediate response,safety and tolerability of the drug were observed.Results:Sixty patients with the Eastern Cooperative Oncology Group PS 0-2(95%)were treated,43 of them were men and 17 were women.The median age was 53 years(range,23-80).Tumor response could not be evaluated in 1 patient.No patient had complete response to the treatment.35(59.3%)have been confirmed as partial response,13(22.0%)had stable disease for more than six months,and 11(18.6%)had progressive disease within six months.The adverse events were mostly mild.The grade 3/4 toxicities were mainly haemorrhage(6.7%),anemia(5.0%),edema(3.3%),abdominal pain(3.3%),diarrhea(3.3%)and nausea(3.3%).Conclusions:Most patients with advanced GISTs achieved clinical benefit and had encouraging immediate responses with imatinib.The treatment was well tolerated.
What problem does this paper attempt to address?